Helen A Watson

Once-daily valacyclovir to reduce the risk of transmission of genital herpes*

Lawrence Corey, Jorma Paavonen, Gregory Mertz, 2004, The New England journal of medicine.

Lessons from resistance analysis in clinical trials of IV zanamivir.

P. Yates, Helen A Watson, Nalini A. L. Mehta, 2023, Virus research.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

A. Wald, O. Keene, L. Corey, 2004, The New England journal of medicine.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Rebecca M. Baker, Phuong Thi Tuyet Nguyen, Carol L. Eyler, 2021, The Lancet Infectious Diseases.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

R. Levine, D. Rockey, H. Makhlouf, 2010, Gastroenterology.

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.

P. Yates, F. Marty, D. Shortino, 2017, The Lancet. Respiratory medicine.

Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza

P. Yates, A. Barth, Helen A Watson, 2019, Clinical and translational science.